Clinical trials: Venetoclax
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
The goal of this study is to compare how well sonrotoclax plus obinutuzumab works versus venetoclax plus rituximab in treating adults with relapsed and/or refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma…
- Trial name
- NCT06943872
- Testing
- Sonrotoclax, Obinutuzumab, Rituximab
- Where
- 195 sites in United States, Argentina and 19 more
- Volunteers
- 630 people
- Sponsor
- BeOne Medicines
Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
MAVRiC Studies 2L Treatment With AV in Patients With CLL/SLL Who Have Relapsed After a Course of BTKi + BCL2i Combination, With or Without Obinutuzumab
This study will evaluate the efficacy and safety of finite-duration acalabrutinib plus venetoclax therapy in patients with relapsed CLL or SLL, who have previously responded to first line (1L) cBTKi + BCL2i therapy (±…
- Trial name
- MAVRiC (NCT07024706)
- Testing
- Acalabrutinib, Venetoclax
- Where
- 47 sites in United States, Austria and 7 more
- Volunteers
- 80 people
- Sponsor
- AstraZeneca
Cancer
A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study
This is an open-label, multicenter, extension study. Patients who are receiving clinical benefit from atezolizumab monotherapy or atezolizumab in combination with other agent(s) or combination/comparator agent(s) during…
- Trial name
- IMbrella B (NCT03768063)
- Testing
- Atezolizumab, Bevacizumab, Alectinib
- Where
- 80 sites in United States, Australia and 22 more
- Volunteers
- 1,000 people
- Sponsor
- Hoffmann-La Roche
B-cell Lymphoma, Chronic Lymphocytic Leukemia
Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies
The study will evaluate NX-5948 (bexobrutideg) in combination with venetoclax with or without an anti-CD20 antibody (rituximab or obinutuzumab) in second-line or higher (2L+) relapsed/refractory (R/R) or first-line (1L) chronic…
- Conditions
- B-cell Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
- Trial name
- NCT07520006
- Testing
- NX-5948, venetoclax, rituximab
- Where
- 6 sites in United States
- Volunteers
- 150 people
- Sponsor
- Nurix Therapeutics, Inc.
Acute Myeloid Leukemia
A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML)
Cancer is a condition where cells in a specific part of the body grow and reproduce uncontrollably. Acute myeloid leukemia (AML) is a cancer of the blood and bone marrow (the spongy tissue inside the bones) that affects white…
- Trial name
- REVIVAL (NCT07581002)
- Testing
- Pivekimab Sunirine, Venetoclax, Azacitidine
- Where
- 38 sites in United States, Austria and 5 more
- Volunteers
- 660 people
- Sponsor
- AbbVie
Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax in Combination With Intravenous (IV) Obinutuzumab or Oral Ibrutinib in Adult Participants With Untreated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Chronic lymphocytic leukemia (CLL) is the most common leukemia in Western countries, representing approximately 30% of all adult leukemias.
- Trial name
- NCT05105841
- Testing
- Venetoclax, Ibrutinib, Obinutuzumab
- Where
- 20 sites in Japan
- Volunteers
- 20 people
- Sponsor
- AbbVie
Acute Myeloid Leukemia
A Study to Investigate Natural Killer Cell Engager (SAR443579) With Different Agents in Participants With Hematological Malignancies
This was a parallel, Phase 1/Phase 2, randomized, open label, multi-cohort, multi-center study assessing the safety, tolerability and preliminary efficacy of SAR443579 with different agents for treatment in adolescent and/or…
- Trial name
- NCT06508489
- Testing
- SAR443579, venetoclax, azacitidine
- Where
- 7 sites in United States, Australia
- Volunteers
- 7 people
- Sponsor
- Sanofi
Acute Myeloid Leukemia (AML)
A Study of Venetoclax in Combination With Low Dose Cytarabine Versus Low Dose Cytarabine Alone in Treatment Naive Patients With Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy
The primary objective of this study is to evaluate if venetoclax when co administered with low-dose cytarabine (LDAC) improves overall survival (OS) versus LDAC and placebo, in treatment-naïve patients with acute myeloid leukemia…
- Trial name
- NCT03069352
- Testing
- Venetoclax, Cytarabine
- Where
- 109 sites in United States, Argentina and 22 more
- Volunteers
- 211 people
- Sponsor
- AbbVie
Acute Myeloid Leukemia, Adult
Study of ADI-PEG 20, Venetoclax and Azacitidine in Acute Myeloid Leukemia
Pegylated arginine deiminase (ADI-PEG 20) will be combined with venetoclax and azacitidine for treatment of subjects with previously treated or untreated with high risk factor acute myeloid leukemia (AML).
- Trial name
- NCT05001828
- Testing
- ADI-PEG 20
- Where
- 3 sites in United States
- Volunteers
- 38 people
- Sponsor
- Polaris Group
Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Chronic Lymphocytic
A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).
The purpose of this study is to assess the safety and tolerability and to confirm the dose of nemtabrutinib in combination with venetoclax in participants with R/R CLL/SLL.
- Conditions
- Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Chronic Lymphocytic, Small-Cell Lymphoma, Lymphoma, Small Lymphocytic
- Trial name
- NCT05947851
- Testing
- Nemtabrutinib, Venetoclax, Rituximab
- Where
- 99 sites in United States, Argentina and 20 more
- Volunteers
- 735 people
- Sponsor
- Merck Sharp & Dohme LLC
CLL
Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)
The main objective of this study is to compare the efficacy of sonrotoclax plus zanubrutinib versus venetoclax plus obinutuzumab in participants with chronic lymphocytic leukemia (CLL)
- Trial name
- NCT06073821
- Testing
- Sonrotoclax, Zanubrutinib, Venetoclax
- Where
- 201 sites in United States, Australia and 19 more
- Volunteers
- 652 people
- Sponsor
- BeOne Medicines
Acute Myeloid Leukemia (AML)
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
Ziftomenib is an investigational drug in development for the treatment of patients with acute myeloid leukemia (AML) with eligible genetic alterations.
- Trial name
- NCT07007312
- Testing
- Ziftomenib, Venetoclax, Azacitidine (AZA)
- Where
- 136 sites in United States, Australia and 15 more
- Volunteers
- 1,300 people
- Sponsor
- Kura Oncology, Inc.
Myelodysplastic Syndromes, Acute Myeloid Leukemia
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
Study ASTX030-01 is a multi-phase study comprising of Phases 1-3 Monotherapy arms, and Phase 1 and Phase 2 Combination Therapy arms.
- Conditions
- Myelodysplastic Syndromes, Acute Myeloid Leukemia, Myelodysplastic Syndrome/Neoplasm, Chronic Myelomonocytic Leukemia
- Trial name
- NCT04256317
- Testing
- Azacitidine, ASTX030 (cedazuridine + azacitidine), Cedazuridine
- Where
- 73 sites in United States, Canada and 8 more
- Volunteers
- 316 people
- Sponsor
- Taiho Oncology, Inc.
Relapsed/Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome
The study is a global, multi-center safety and efficacy trial of epcoritamab, an antibody also known as EPKINLY™ and GEN3013 (DuoBody®-CD3xCD20).
- Conditions
- Relapsed/Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Richter's Syndrome, Treatment-naïve High Risk Chronic Lymphocytic Leukemia
- Trial name
- EPCORE™ CLL-1 (NCT04623541)
- Testing
- Epcoritamab, rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone, Venetoclax
- Where
- 81 sites in United States, Australia and 10 more
- Volunteers
- 194 people
- Sponsor
- Genmab
Acute Myeloid Leukemia
Pharmacokinetics, Safety, and Efficacy of ASTX727 in Combination With Venetoclax in Acute Myeloid Leukemia (AML)
The Phase 1 portion of this study is a single-arm, open-label, multicenter, non-randomized interventional study to evaluate the pharmacokinetic (PK) interaction, safety, and efficacy of ASTX727 when given in combination with…
- Trial name
- NCT04657081
- Testing
- Decitabine and Cedazuridine (ASTX727), Venetoclax
- Where
- 34 sites in United States, Canada and 1 more
- Volunteers
- 101 people
- Sponsor
- Taiho Oncology, Inc.
Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia
This study will assess the safety, tolerability, pharmaokinetics, and preliminary efficacy of mosunetuzumab (Lunsumio) monotherapy in participants with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) or small…
- Trial name
- NCT05091424
- Testing
- Mosunetuzumab, Tocilizumab, Venetoclax
- Where
- 31 sites in United States, Australia and 8 more
- Volunteers
- 332 people
- Sponsor
- Hoffmann-La Roche
Chronic Lymphocytic Leukemia
Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL
The purpose of this study is to evaluate the efficacy and safety of acalabrutinib in combination with venetoclax and acalabrutinib in combination with venetoclax with and without obinutuzumab compared to chemoimmunotherapy in…
- Trial name
- AMPLIFY (NCT03836261)
- Testing
- Acalabrutinib, Venetoclax, Chemoimmunotherapy
- Where
- 169 sites in United States, Argentina and 25 more
- Volunteers
- 984 people
- Sponsor
- Acerta Pharma BV
Acute Myeloid Leukemia, Myelodysplastic Syndrome
Study of BMS-986497 (ORM-6151) as a Monotherapy, in Double and Triple Combination With Azacitidine and Venetoclax in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
The purpose of this study is to assess the safety, tolerability, drug levels, drug efficacy and determine the recommended dose of BMS-986497 as a monotherapy, in double combination with Azacitidine and in triple combination with…
- Trial name
- NCT06419634
- Testing
- BMS-986497, Azacitidine, Venetoclax
- Where
- 10 sites in United States, Canada and 1 more
- Volunteers
- 34 people
- Sponsor
- Bristol-Myers Squibb
Small Cell Lung Cancer ( SCLC ), Neuroendocrine Cancer
TLN-499 in Combination With Venetoclax in Patients With Relapsed/Refractory Solid Tumors
The purpose of this first-in-human study is to evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of TLN-499 in combination with venetoclax in participants with relapsed/refractory solid…
- Conditions
- Small Cell Lung Cancer ( SCLC ), Neuroendocrine Cancer, Malignant Pleural Mesotheliomas (Mpm), Synovial Sarcomas
- Trial name
- NCT07713732
- Testing
- TLN-499, Venetoclax
- Where
- 3 sites in Australia
- Volunteers
- 120 people
- Sponsor
- Treeline Biosciences, Inc.
Leukemia, Lymphocytic, Chronic, B-Cell
A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
The purpose of this study is to assess progression-free survival (PFS) from treatment with ibrutinib plus venetoclax (I+VEN) compared with obinutuzumab plus chlorambucil (G-Clb) as assessed by an Independent Review Committee…
- Trial name
- GLOW (NCT03462719)
- Testing
- Ibrutinib, Venetoclax, Chlorambucil
- Where
- 88 sites in United States, Belgium and 12 more
- Volunteers
- 211 people
- Sponsor
- Janssen Research & Development, LLC